{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.08","value":"10.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"}],"units":"Participants"}],"description":"Change in health-related quality of life events were reported by participants using the Functional Assessment of Cancer Therapy: Lymphoma Subscale (FACT-LymS) assessment tool. Results are presented as the mean (SD) best change from baseline. The best change from baseline was defined as the highest change score (improvement) after baseline.\n\nThe FACT-LymS is on a scale from 0-60, with higher scores associated with a better quality of life. It incorporates values from 15 questions, each rated 0-4, related to study indications.","dispersionType":"Standard Deviation","groups":[{"description":"Idelalisib 150 mg tablet administered orally twice daily until tumor progression or development of unacceptable toxicity.","id":"OG000","title":"Idelalisib"}],"paramType":"MEAN","populationDescription":"Participants in the ITT Analysis Set with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline to End of Treatment (up to 81 months)","title":"Change in Health-Related Quality of Life Using the Functional Assessment of Cancer Therapy: Lymphoma Subscale (FACT-LymS)","type":"SECONDARY","unitOfMeasure":"units on a scale"}